Navigation Links
Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
Date:8/13/2012

IRVINE, Calif., Aug. 13, 2012 /PRNewswire/ -- Antigen Discovery, Inc. (ADi) today announced that it has received a Phase II Small Business Innovation and Research (SBIR) award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. The three-year award, totaling approximately $ 2.5 million, is a continuation of a Phase I SBIR grant to scan the Plasmodium falciparum proteome for protective antigens. The funds will support a collaborative research effort between ADi and Sanaria, Inc. to use ADi's proteome microarrays to identify biomarkers associated with responses to the administration of Sanaria's malaria products in human trials, including Sanaria® PfSPZ Vaccine (radiation attenuated sporozoites), Sanaria® PfSPZ Challenge (fully infectious sporozoites), and Sanaria® PfSPZ-CVac (PfSPZ Challenge administered with malaria chemoprophylaxis).  An effective malaria vaccine would greatly benefit the billions at risk throughout the world. "By comparing the serum antibody profiles from vaccinees who are protected with those who are not, we aim to identify surrogate antibody biomarkers associated with sporozoite vaccine mediated protection. Such markers are a critically important component of vaccine development," states Dr. Philip Felgner, Principal Investigator, Founder and Chairman of ADi. According to Dr. Stephen L. Hoffman, Sanaria's Founder and Chief Scientific Officer, "This is an unprecedented opportunity to exploit ADi's unique technology to advance our understanding of protective immunity against malaria, and thereby accelerate development and licensure of a highly effective malaria vaccine."   

Additionally, serum samples will be analyzed from clinical studies conducted at Radboud University Nijmengen Medical Center (RUNMC) in the Netherlands, in which volunteers were completely protected after being immunized by the bite of mosquitoes carrying viable (non-irradiated) PfSPZ while taking chloroquine chemoprophylaxis to prevent blood stage infection. The protection lasted for 2 years.  Dr. Robert Sauerwein, director of the RUNMC studies, stated "This is a very exciting opportunity to gain significant insights into how PfSPZ works to provide robust protection against malaria."  

"We are pleased and privileged to have the opportunity to work with the Sanaria and RUNMC teams on this exciting project and grateful for continued support from the NIAID," said Dr. Xiaowu Liang, President and CEO of ADi.  "We aim to develop a diagnostic test that can predict vaccine mediated protection, and to identify antigens that may be used to produce an effective subunit vaccine."

About Antigen Discovery, Inc.

Antigen Discovery, Inc. is a privately owned biotechnology company located in Irvine, California. ADi has a proprietary high throughput proteomics platform technology for biomarker discovery. The company uses and commercializes its innovative proteome microarrays and testing models to facilitate the development of new diagnostic tests, therapeutics and vaccines for infectious disease, autoimmunity, cancer and more. For more information about ADi see http://www.antigendiscovery.com

Contact:

Angela Yee
ayee@antigendiscovery.com

About Sanaria, Inc.

Sanaria's mission is to develop and commercialize live, whole sporozoite vaccines against malaria. Sanaria's sporozoite based products are being tested in clinical trials in the United States, Africa and Europe. Sanaria also makes available to the research community a range of parasitological and entomological reagents and assay services. For more information, see http://www.sanaria.com.

Contact:

Adam Richman, Ph.D.
arichman@sanaria.com 


'/>"/>
SOURCE Antigen Discovery, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
2. Generex Augments Antigen Express Scientific Advisory Board
3. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
4. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
5. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
6. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
7. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
8. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
9. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
10. Turner Construction Company Awarded Fort Irwin Replacement Hospital
11. Spot On Sciences Awarded $1 Million DARPA Grant to Develop a Blood Sample Collection Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)...  The blood testing market in China ... Information and The Freedonia Group in a recent report.  ... The healthcare research firm said that China ... stations and in improving testing at the provincial level.  ... Blood Testing Market in China , which ...
(Date:4/28/2016)... JERUSALEM , April 28, 2016 ... ), a clinical-stage pharmaceutical company focused on the development of ... participate in the upcoming PIONEERS 2016 conference, presented by ... 5, 2016 in New York . ... overview at the conference. Presentation Details:   ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions is ... of Microsoft Dynamics GP for one their long-term care clients. Working together with ... GP with key clinical management systems, and delivered a fully integrated accounting and ...
(Date:4/29/2016)... ... 29, 2016 , ... The number of chronically and seriously ill individuals is ... is an urgent need for highly skilled care managers and care coordinators. ... to train and retain care managers, and enhance their skills. , Care ...
(Date:4/28/2016)... ... April 28, 2016 , ... The Dentists Insurance Company ... signed a letter of intent with Moda to acquire Dentists Benefits ... , Started by dentists 36 years ago, TDIC focuses exclusively on supporting the ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic Arts’ gymnast, Brooklyn Varize, ... will be held at the University of Montana on April 28-May 1. Varize will ... River. , In order to qualify, Varize needed to place top seven all-around in ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... for Tobacco-Free Kids, a leading force in the fight to reduce tobacco use ... local policies that can help reduce tobacco use. The initiative brings together two ...
Breaking Medicine News(10 mins):